Plus Therapeutics Boosts Cash Position, Expands CNSide Coverage
Event summary
- Plus Therapeutics raised $15 million in a January 2026 public offering, increasing cash balance to $15.1 million by Q1 2026.
- CNSide diagnostic coverage expanded to 81 million lives with new payer agreements, including Blue Shield of California.
- FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas, broadening scope beyond initial request.
- Company added SpectronRx as a second GMP manufacturing site for REYOBIQ, enhancing supply chain resilience.
The big picture
Plus Therapeutics is positioning itself as a key player in targeted radiotherapeutics for CNS cancers, leveraging strategic payer agreements and FDA designations to drive commercial adoption. The company's focus on both diagnostic and therapeutic solutions reflects broader industry trends toward precision medicine, particularly in rare and difficult-to-treat cancers. With $15.1 million in cash as of Q1 2026, Plus appears well-capitalized to pursue its 2026 milestones, though execution risks remain in scaling commercial operations and advancing clinical trials.
What we're watching
- Commercial Scale
- Whether Plus can sustain the pace of CNSide commercial expansion while maintaining profitability.
- Regulatory Pathway
- How FDA feedback will shape the pivotal trial framework for REYOBIQ in leptomeningeal metastases.
- Execution Risk
- The company's ability to meet 2026 milestones, including REYOBIQ Phase 2 trial completion and CNSide test order growth.
Related topics